Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity

Marshall P. Goren, Arlene A. Forastiere, Reba K. Wright, Marc E. Horowitz, Richard K. Dodge, Barton A. Kamen, Mary J. Viar, Charles B. Pratt

Research output: Contribution to journalArticle

Abstract

We compared the acute tubular nephrotoxicity of three platinum compounds in children and adults with solid tumors by monitoring the urinary excretion of alanine aminopeptidase, N-acetyl-β-D-glucosaminidase, and total protein. Cisplatin (100 mg/m2) was administered with mannitol, or at a twofold larger total dosage (50 mg/m2 per day for 4 days) in a 3% saline infusion. Carboplatin (300 mg/m2) was administered in combination with 5-fluorouracil, and iproplatin was administered in dosages ranging from 216 to 388 mg/m2. Enzymuria and proteinuria induced by cisplatin at a total dosage of 200 mg/m2 on a divided schedule did not significantly differ from that observed for the single 100 mg/m2 dose. Enzymuria and proteinuria induced by carboplatin and iproplatin were significantly less than that for cisplatin; however, one patient developed chronic tubular damage after three courses of carboplatin, and the acute tubular toxicity of iproplatin in one of 15 patients was exceptional. Our findings support the value of administering cisplatin in hypertonic saline on a divided schedule as a strategy to reduce acute tubular damage. Although carboplatin and iproplatin are less nephrotoxic than cisplatin, occasionally patients experience subclinical acute or chronic tubular damage that may lead to overt nephrotoxicity with continued therapy.

Original languageEnglish (US)
Pages (from-to)57-60
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume19
Issue number1
DOIs
StatePublished - Feb 1987
Externally publishedYes

Fingerprint

Carboplatin
Cisplatin
CD13 Antigens
Proteinuria
Appointments and Schedules
Platinum Compounds
Hexosaminidases
Mannitol
Fluorouracil
Toxicity
Tumors
iproplatin
Monitoring
Neoplasms
Proteins

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity. / Goren, Marshall P.; Forastiere, Arlene A.; Wright, Reba K.; Horowitz, Marc E.; Dodge, Richard K.; Kamen, Barton A.; Viar, Mary J.; Pratt, Charles B.

In: Cancer Chemotherapy and Pharmacology, Vol. 19, No. 1, 02.1987, p. 57-60.

Research output: Contribution to journalArticle

Goren, Marshall P. ; Forastiere, Arlene A. ; Wright, Reba K. ; Horowitz, Marc E. ; Dodge, Richard K. ; Kamen, Barton A. ; Viar, Mary J. ; Pratt, Charles B. / Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity. In: Cancer Chemotherapy and Pharmacology. 1987 ; Vol. 19, No. 1. pp. 57-60.
@article{c42ba0dc7bb94b9a90e43777a17fa70e,
title = "Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity",
abstract = "We compared the acute tubular nephrotoxicity of three platinum compounds in children and adults with solid tumors by monitoring the urinary excretion of alanine aminopeptidase, N-acetyl-β-D-glucosaminidase, and total protein. Cisplatin (100 mg/m2) was administered with mannitol, or at a twofold larger total dosage (50 mg/m2 per day for 4 days) in a 3{\%} saline infusion. Carboplatin (300 mg/m2) was administered in combination with 5-fluorouracil, and iproplatin was administered in dosages ranging from 216 to 388 mg/m2. Enzymuria and proteinuria induced by cisplatin at a total dosage of 200 mg/m2 on a divided schedule did not significantly differ from that observed for the single 100 mg/m2 dose. Enzymuria and proteinuria induced by carboplatin and iproplatin were significantly less than that for cisplatin; however, one patient developed chronic tubular damage after three courses of carboplatin, and the acute tubular toxicity of iproplatin in one of 15 patients was exceptional. Our findings support the value of administering cisplatin in hypertonic saline on a divided schedule as a strategy to reduce acute tubular damage. Although carboplatin and iproplatin are less nephrotoxic than cisplatin, occasionally patients experience subclinical acute or chronic tubular damage that may lead to overt nephrotoxicity with continued therapy.",
author = "Goren, {Marshall P.} and Forastiere, {Arlene A.} and Wright, {Reba K.} and Horowitz, {Marc E.} and Dodge, {Richard K.} and Kamen, {Barton A.} and Viar, {Mary J.} and Pratt, {Charles B.}",
year = "1987",
month = "2",
doi = "10.1007/BF00296257",
language = "English (US)",
volume = "19",
pages = "57--60",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity

AU - Goren, Marshall P.

AU - Forastiere, Arlene A.

AU - Wright, Reba K.

AU - Horowitz, Marc E.

AU - Dodge, Richard K.

AU - Kamen, Barton A.

AU - Viar, Mary J.

AU - Pratt, Charles B.

PY - 1987/2

Y1 - 1987/2

N2 - We compared the acute tubular nephrotoxicity of three platinum compounds in children and adults with solid tumors by monitoring the urinary excretion of alanine aminopeptidase, N-acetyl-β-D-glucosaminidase, and total protein. Cisplatin (100 mg/m2) was administered with mannitol, or at a twofold larger total dosage (50 mg/m2 per day for 4 days) in a 3% saline infusion. Carboplatin (300 mg/m2) was administered in combination with 5-fluorouracil, and iproplatin was administered in dosages ranging from 216 to 388 mg/m2. Enzymuria and proteinuria induced by cisplatin at a total dosage of 200 mg/m2 on a divided schedule did not significantly differ from that observed for the single 100 mg/m2 dose. Enzymuria and proteinuria induced by carboplatin and iproplatin were significantly less than that for cisplatin; however, one patient developed chronic tubular damage after three courses of carboplatin, and the acute tubular toxicity of iproplatin in one of 15 patients was exceptional. Our findings support the value of administering cisplatin in hypertonic saline on a divided schedule as a strategy to reduce acute tubular damage. Although carboplatin and iproplatin are less nephrotoxic than cisplatin, occasionally patients experience subclinical acute or chronic tubular damage that may lead to overt nephrotoxicity with continued therapy.

AB - We compared the acute tubular nephrotoxicity of three platinum compounds in children and adults with solid tumors by monitoring the urinary excretion of alanine aminopeptidase, N-acetyl-β-D-glucosaminidase, and total protein. Cisplatin (100 mg/m2) was administered with mannitol, or at a twofold larger total dosage (50 mg/m2 per day for 4 days) in a 3% saline infusion. Carboplatin (300 mg/m2) was administered in combination with 5-fluorouracil, and iproplatin was administered in dosages ranging from 216 to 388 mg/m2. Enzymuria and proteinuria induced by cisplatin at a total dosage of 200 mg/m2 on a divided schedule did not significantly differ from that observed for the single 100 mg/m2 dose. Enzymuria and proteinuria induced by carboplatin and iproplatin were significantly less than that for cisplatin; however, one patient developed chronic tubular damage after three courses of carboplatin, and the acute tubular toxicity of iproplatin in one of 15 patients was exceptional. Our findings support the value of administering cisplatin in hypertonic saline on a divided schedule as a strategy to reduce acute tubular damage. Although carboplatin and iproplatin are less nephrotoxic than cisplatin, occasionally patients experience subclinical acute or chronic tubular damage that may lead to overt nephrotoxicity with continued therapy.

UR - http://www.scopus.com/inward/record.url?scp=0023158676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023158676&partnerID=8YFLogxK

U2 - 10.1007/BF00296257

DO - 10.1007/BF00296257

M3 - Article

C2 - 2880677

AN - SCOPUS:0023158676

VL - 19

SP - 57

EP - 60

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -